Cixutumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade from ProteoGenix; catalogue PX-TA1205; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introduction to Cixutumumab Biosimilar – A Promising Antibody for Targeting IGF1R Cixutumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a monoclonal antibody that has shown great potential in the field of cancer therapy. This biosimilar is designed to target the insulin-like growth factor-1 receptor (IGF1R), a protein that plays a crucial role in cell growth and survival. In this article, we will discuss the structure, activity, and potential applications of Cixutumumab Biosimilar.
Cixutumumab Biosimilar is a humanized IgG1 monoclonal antibody, which means that it is derived from human antibodies and has been modified to reduce potential immune reactions in patients. The antibody is composed of two heavy chains and two light chains, connected by disulfide bonds. It has a molecular weight of approximately 150 kDa.
Cixutumumab Biosimilar specifically targets the IGF1R, a transmembrane receptor that is expressed on the surface of many types of cancer cells. This receptor is activated by the binding of insulin-like growth factors (IGF) and plays a crucial role in promoting cell growth and survival. Overexpression of IGF1R has been linked to the development and progression of various types of cancer, making it a promising therapeutic target.
By binding to IGF1R, Cixutumumab Biosimilar inhibits the binding of IGF and blocks the downstream signaling pathways that promote cancer cell growth and survival. This leads to the inhibition of tumor growth and ultimately, cancer cell death. Additionally, Cixutumumab Biosimilar has been shown to enhance the activity of other cancer treatments, such as chemotherapy and radiation therapy, making it a potential combination therapy for cancer treatment.
Cixutumumab Biosimilar is currently being studied in clinical trials for the treatment of various types of cancer, including lung, breast, and prostate cancer. Preliminary results have shown promising anti-tumor activity, with some patients experiencing tumor shrinkage and prolonged survival. It is also being investigated as a potential treatment for pediatric cancers, such as Ewing’s sarcoma and neuroblastoma.
In addition to its potential as a standalone therapy, Cixutumumab Biosimilar is also being studied in combination with other cancer treatments. Preclinical studies have shown that combining Cixutumumab Biosimilar with chemotherapy or radiation therapy can enhance their anti-tumor effects, making it a potential adjuvant therapy for cancer treatment.
Cixutumumab Biosimilar, also known as Anti-IGF1R, CD221 mAb – Research Grade, is a promising antibody that specifically targets the insulin-like growth factor-1 receptor (IGF1R). Its unique structure and mechanism of action make it a potential therapy for various types of cancer. As further research and clinical trials are conducted, Cixutumumab Biosimilar has the potential to become a valuable addition to the arsenal of treatments for cancer patients.
ProteoGenix catalogue number PX-TA1205. For research use only.
Target: Cixutumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cixutumumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
